J&J's single-shot COVID-19 vaccine is 66% effective globally and 72% effective in the U.S in preventing moderate and severe COVID-19 infections.
The test results were disclosed based on the clinical trials conducted on 44,000 participants in the U.S, Latin America, and South Africa. It was found that the vaccine was 72% effective in the U.S, 66% in Latin America, and 57% in South Africa, 28 days after vaccination. The overall effectiveness of the J&J vaccine is 66% compared to the other two vaccines which showed average effectiveness of 95%. The J&J vaccine can be stored in standard refrigerators at temperatures of 2 to 8 degrees Celsius, making it easier and cheaper to transport and store.
According to the analysis, the vaccine was effective after 14 days, and there was no hospitalization or deaths in the vaccinated group post 28 days following vaccination. Johnson & Johnson said in a release that there are no serious side effects linked to the vaccine, and it is found to be effective across all racial groups, including Black and Latino participants and continents. The vaccine has got approval both in the U.S and in the EU and is expected to ease the supply shortage.
We mark the claim as Patly True as the vaccine is 72% effective only in the U.S and not across all continents.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.